{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&max-date=2018-05-02", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&max-date=2018-05-02", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&max-date=2018-05-02&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&_page=0&max-date=2018-05-02", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&max-date=2018-05-02", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&max-date=2018-05-02", "items" : [{"_about" : "http://data.parliament.uk/resources/896497", "AnsweringBody" : [{"_value" : "Department for Environment, Food and Rural Affairs"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/896497/answer", "answerText" : {"_value" : "<p>A decision on the appointment of the national Tree Champion, including to whom that person will report, will be made in due course.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3934", "label" : {"_value" : "Biography information for George Eustice"}
        }
        , "answeringMemberConstituency" : {"_value" : "Camborne and Redruth"}
        , "answeringMemberPrinted" : {"_value" : "George Eustice"}
        , "dateOfAnswer" : {"_value" : "2018-05-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-05-10T14:19:22.637Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "13"}
      , "answeringDeptShortName" : {"_value" : "Environment, Food and Rural Affairs"}
      , "answeringDeptSortName" : {"_value" : "Environment, Food and Rural Affairs"}
      , "date" : {"_value" : "2018-05-02", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Forestry"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Environment, Food and Rural Affairs, when he plans to appoint the national tree champion; and to whom that person will report.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "140695"}
    , {"_about" : "http://data.parliament.uk/resources/896505", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/896505/answer", "answerText" : {"_value" : "<p>Early diagnosis of blood cancers is difficult as symptoms, such as tiredness or back pain, are often misdiagnosed. For suspected blood cancers, the National Institute for Health and Care Excellence published a revised guideline in 2015 which clearly sets out that general practitioners should consider a very urgent full blood count within 48 hours to assess for leukaemia if adults present with suspicious symptoms.<\/p><p> <\/p><p>In December 2016 NHS England announced transformation funding of £200 million for Cancer Alliances to encourage new and innovative ways to diagnose cancer earlier, improve the care for those living with cancer and ensure that each cancer patient gets the right care for them.<\/p><p> <\/p><p>Additionally, the Accelerate, Coordinate and Evaluate Programme is a unique early diagnosis initiative, a programme of 60 projects exploring innovative concepts of diagnosing cancer earlier across England. The programme is testing a new multi-disciplinary diagnostic centre approach to diagnosing patients with vague or unclear but concerning symptoms, often characteristic of hard to diagnose cancers like blood cancers.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-05-14", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-05-14T11:23:24.86Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-05-02", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Blood Cancer"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans his Department has to ensure people with blood cancer are diagnosed as soon as possible.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "140696"}
    , {"_about" : "http://data.parliament.uk/resources/896506", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/896506/answer", "answerText" : {"_value" : "<p>The Recovery Package is designed to help patients and clinicians assess a patient\u2019s holistic needs and plan appropriately for their care and support. It includes a Holistic Needs Assessment (HNA) and Care Plan. This guides a conversation about the person\u2019s holistic needs (physical, psychosocial, financial and social) in order to identify any concerns. An HNA should take place within 31 days of diagnosis and at the end of each acute phase of treatment and the Care Plan updated each time. The Recovery Package is being commissioned and delivered in full or in part by many clinical commissioning groups and providers across England. Our aim now is to accelerate the process, to ensure full implementation by 2020 - available to all cancer patients.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-05-14", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "140698"}
        , {"_value" : "140700"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-05-14T11:25:00.19Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-05-02", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Blood Cancer: Mental Health Services"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that (a) emotional and (b) psychological support is provided to people who have blood cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "140697"}
    , {"_about" : "http://data.parliament.uk/resources/896508", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/896508/answer", "answerText" : {"_value" : "<p>The Recovery Package is designed to help patients and clinicians assess a patient\u2019s holistic needs and plan appropriately for their care and support. It includes a Holistic Needs Assessment (HNA) and Care Plan. This guides a conversation about the person\u2019s holistic needs (physical, psychosocial, financial and social) in order to identify any concerns. An HNA should take place within 31 days of diagnosis and at the end of each acute phase of treatment and the Care Plan updated each time. The Recovery Package is being commissioned and delivered in full or in part by many clinical commissioning groups and providers across England. Our aim now is to accelerate the process, to ensure full implementation by 2020 - available to all cancer patients.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-05-14", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "140697"}
        , {"_value" : "140700"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-05-14T11:25:00.237Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-05-02", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Blood Cancer"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that the cancer recovery package meets the needs of people with blood cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "140698"}
    , {"_about" : "http://data.parliament.uk/resources/896509", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/896509/answer", "answerText" : {"_value" : "<p>Public Health England and NHS England developed the first iteration of the cancer dashboard in response to recommendations in the Independent Cancer Taskforce report \u2018Achieving world-class cancer outcomes: a strategy for England 2015-2020\u2019. This includes data on breast, colorectal, lung and prostate cancers. Further cancer sites, including blood cancer, were not included because of the risk of making patients identifiable when viewing data for individual hospitals or clinical commissioning groups.<\/p><p> <\/p><p>A second iteration of the dashboard is being considered by the National Cancer Transformation Board with a wider ambition to include rarer cancers and cancers with a lower incidence, such a blood cancers, as the dashboard develops.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-05-14", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-05-14T11:28:20.29Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-05-02", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Blood Cancer"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans his Department has to widen the cancer dashboard to include blood cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "140699"}
    , {"_about" : "http://data.parliament.uk/resources/896511", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/896511/answer", "answerText" : {"_value" : "<p>The Recovery Package is designed to help patients and clinicians assess a patient\u2019s holistic needs and plan appropriately for their care and support. It includes a Holistic Needs Assessment (HNA) and Care Plan. This guides a conversation about the person\u2019s holistic needs (physical, psychosocial, financial and social) in order to identify any concerns. An HNA should take place within 31 days of diagnosis and at the end of each acute phase of treatment and the Care Plan updated each time. The Recovery Package is being commissioned and delivered in full or in part by many clinical commissioning groups and providers across England. Our aim now is to accelerate the process, to ensure full implementation by 2020 - available to all cancer patients.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-05-14", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "140697"}
        , {"_value" : "140698"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-05-14T11:25:00.3Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-05-02", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Blood Cancer"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what support his Department provides to people diagnosed with blood cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "140700"}
    , {"_about" : "http://data.parliament.uk/resources/896513", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/896513/answer", "answerText" : {"_value" : "<p>In England there is a well-established framework for enabling access to cost effective new cancer medicines. All new licensed cancer medicines are referred to the National Institute for Health and Care Excellence (NICE) for inclusion within the Technology Appraisal Programme. This referral is irrespective of the clinical indication concerned. Where cancer medicines are approved by NICE for use in England, NHS England makes these available immediately. NICE now also has the ability to refer licensed medicines demonstrating promising, but not yet certain, benefits for inclusion within the Cancer Drugs Fund.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-05-14", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-05-14T15:37:08.063Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-05-02", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Blood Cancer"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of funding for providing new treatments for blood cancer.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "140701"}
    , {"_about" : "http://data.parliament.uk/resources/892165", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/892165/answer", "answerText" : {"_value" : "<p>From 1 April 2018, the National Living Wage and National Minimum Wage increased above inflation to give more than two million of the lowest paid workers a pay rise of over 2 per cent in real terms. Over the next 12 months, full time workers aged 25 and over on the National Living Wage will see their earnings grow by more than £600.<\/p><p> <\/p><p>In the longer term, the Government\u2019s ambitious, modern Industrial Strategy sets out a long-term plan to boost the productivity and earning power of people throughout the UK. It sets out how we will help businesses create better, higher-paying jobs with investment in the skills, industries and infrastructure of the future.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3936", "label" : {"_value" : "Biography information for Andrew Griffiths"}
        }
        , "answeringMemberConstituency" : {"_value" : "Burton"}
        , "answeringMemberPrinted" : {"_value" : "Andrew Griffiths"}
        , "dateOfAnswer" : {"_value" : "2018-05-03", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-05-03T15:33:37.663Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "201"}
      , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"}
      , "date" : {"_value" : "2018-04-26", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Low Pay"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what steps his Department is taking to tackle low pay.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "138424"}
    , {"_about" : "http://data.parliament.uk/resources/872272", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/872272/answer", "answerText" : {"_value" : "<p>The following treatments are routinely available, having undergone Technical Appraisals by the National Institute for Health and Care Excellence (NICE). They were previously accessible through the Cancer Drugs Fund.<\/p><p> <\/p><p>- Blinatumomab for relapsed refractory (r/r) Philadelphia negative acute lymphoblastic leukaemia (ALL); and<\/p><p>- Ponatinib for Philadelphia positive ALL in patients in whom imatinib is not clinically appropriate (which might cover some r/r).<\/p><p> <\/p><p>The following treatments are currently under consideration by NICE:<\/p><p> <\/p><p>- CAR-T (Tisagenlecleucel-T and also Axicabtagene ciloleucel) for previously treated B-cell ALL in people aged 3 to 21 at initial diagnosis;<\/p><p>- Inotuzumab ozogamicin for treating r/r ALL; and<\/p><p>- Blinatumomab in other extended indications in ALL.<\/p><p> <\/p><p>Finally, the following treatments are currently accessible through the Cancer Drugs Fund.<\/p><p> <\/p><p>- Clofarabine for treating ALL in children after two therapies; and<\/p><p>- Nelarabine for treating ALL after two therapies.<\/p><p> <\/p><p>Information on the number and proportion of patients with refractory B-cell Acute Lymphoblastic Leukaemia who have been unable to access treatments for that condition is not held centrally.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-04-03", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "134187"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-04-03T13:25:08.103Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-03-26", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Acute Lymphoblastic Leukaemia: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the availability of treatments for patients diagnosed with Refractory B-cell Acute Lymphoblastic Leukaemia.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "134186"}
    , {"_about" : "http://data.parliament.uk/resources/872273", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/872273/answer", "answerText" : {"_value" : "<p>The following treatments are routinely available, having undergone Technical Appraisals by the National Institute for Health and Care Excellence (NICE). They were previously accessible through the Cancer Drugs Fund.<\/p><p> <\/p><p>- Blinatumomab for relapsed refractory (r/r) Philadelphia negative acute lymphoblastic leukaemia (ALL); and<\/p><p>- Ponatinib for Philadelphia positive ALL in patients in whom imatinib is not clinically appropriate (which might cover some r/r).<\/p><p> <\/p><p>The following treatments are currently under consideration by NICE:<\/p><p> <\/p><p>- CAR-T (Tisagenlecleucel-T and also Axicabtagene ciloleucel) for previously treated B-cell ALL in people aged 3 to 21 at initial diagnosis;<\/p><p>- Inotuzumab ozogamicin for treating r/r ALL; and<\/p><p>- Blinatumomab in other extended indications in ALL.<\/p><p> <\/p><p>Finally, the following treatments are currently accessible through the Cancer Drugs Fund.<\/p><p> <\/p><p>- Clofarabine for treating ALL in children after two therapies; and<\/p><p>- Nelarabine for treating ALL after two therapies.<\/p><p> <\/p><p>Information on the number and proportion of patients with refractory B-cell Acute Lymphoblastic Leukaemia who have been unable to access treatments for that condition is not held centrally.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-04-03", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "134186"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-04-03T13:25:08.167Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-03-26", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Acute Lymphoblastic Leukaemia: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, how many and what proportion of patients with Refractory B-cell Acute Lymphoblastic Leukaemia have been unable to access treatments for that condition.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
      }
      , "tablingMemberConstituency" : {"_value" : "Crawley"}
      , "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
      ], "uin" : "134187"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Henry+Smith&_page=1&max-date=2018-05-02", "page" : 0, "startIndex" : 1, "totalResults" : 249, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}